NLNK Profile
NewLink
Genetics Corporation (NLNK) is a biopharmaceutical company that is
focused on discovering, developing, and commercializing novel
immuno-oncology products. The company's pipeline includes a range of
immunotherapeutic candidates designed to stimulate the body's immune
system to fight cancer.
NewLink Genetics has several product
candidates in various stages of clinical development, including
NLG207, a nanoparticle liposome formulation of the chemotherapy agent
docetaxel, NLG802, a prodrug of indoximod, and NLG919, an IDO pathway
inhibitor. The company also has several preclinical candidates in
development, including a cancer vaccine designed to target the
survivin protein.
NewLink Genetics has partnerships with
several other biopharmaceutical companies, including Roche and Merck,
to develop and commercialize its products. The company is
headquartered in Ames, Iowa, and was found
|
